AR056020A1 - Formulaciones liquidas - Google Patents
Formulaciones liquidasInfo
- Publication number
- AR056020A1 AR056020A1 ARP060103432A ARP060103432A AR056020A1 AR 056020 A1 AR056020 A1 AR 056020A1 AR P060103432 A ARP060103432 A AR P060103432A AR P060103432 A ARP060103432 A AR P060103432A AR 056020 A1 AR056020 A1 AR 056020A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- concentrate
- concentrate according
- phenyl
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se describe un concentrado para dilucion, que comprende un agonista del receptor S1P o una sal farmacéuticamente aceptable del mismo, glicol propilénico y opcionalmente glicerina. Esta formulacion está adaptada para pacientes que tienen una condicion de dificultad para tragar. Reivindicacion 1: Un concentrado para dilucion que comprende un modulador o agonista del receptor S1P o una sal farmacéuticamente aceptable del mismo, y glicol propilénico. Reivindicacion 3: Un concentrado de acuerdo con la reivindicacion 1 o 2, en donde el modulador o agonista del receptor S1P es un compuesto que comprende un grupo de la formula (10) en donde Z es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, fenilo, fenilo sustituido por OH, alquilo C1-6 sustituido por 1 a 3 sustituyentes seleccionados del grupo que consiste en halogeno, cicloalquilo C3-8, fenilo y fenilo sustituido por OH, o CH2-R4z en donde R4z es OH, aciloxi o un residuo de la formula (a) en donde Z1 es un enlace directo u O, preferiblemente O; cada uno de R5z y R6z, independientemente, es H o alquilo C1-4 opcionalmente sustituido por 1, 2 o 3 átomos de halogeno; R1z es OH, aciloxi o un residuo de la formula (a); y cada uno de R2z y R3z independientemente, es H alquilo C1-4 o acilo, o una sal farmacéuticamente aceptable del mismo. Reivindicacion 7: Una solucion farmacéutica que comprende un concentrado de acuerdo con cualquiera de las reivindicaciones 1 o 2, diluido con un vehículo en una relacion de más de 1:10. Reivindicacion 9: El uso de un concentrado d acuerdo con cualquiera de las reivindicaciones 1 o 2, para la preparacion de un medicamento para el tratamiento de un sujeto con la necesidad de inmunosupresion. Reivindicacion 10: Un método para el tratamiento de un sujeto con la necesidad de inmunosupresion, que comprende administrar al sujeto un concentrado de acuerdo con la reivindicacion 1 o 2, el cual se diluye con un vehículo en una relacion de 1:1 a más de 1:10 antes de administracion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70682005P | 2005-08-09 | 2005-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056020A1 true AR056020A1 (es) | 2007-09-12 |
Family
ID=37734410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103432A AR056020A1 (es) | 2005-08-09 | 2006-08-07 | Formulaciones liquidas |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20080194526A1 (es) |
| EP (1) | EP1915130B1 (es) |
| JP (1) | JP5068755B2 (es) |
| KR (1) | KR101473494B1 (es) |
| CN (1) | CN101237852B (es) |
| AR (1) | AR056020A1 (es) |
| AU (1) | AU2006280138B2 (es) |
| BR (1) | BRPI0615009A2 (es) |
| CA (1) | CA2618018C (es) |
| EC (1) | ECSP088165A (es) |
| GT (1) | GT200600350A (es) |
| IL (1) | IL188915A0 (es) |
| MA (1) | MA29736B1 (es) |
| MX (1) | MX2008001967A (es) |
| MY (1) | MY145111A (es) |
| NO (1) | NO20081218L (es) |
| NZ (2) | NZ565696A (es) |
| PE (2) | PE20070337A1 (es) |
| RU (2) | RU2470631C2 (es) |
| TN (1) | TNSN08061A1 (es) |
| TW (1) | TWI317289B (es) |
| WO (1) | WO2007021666A2 (es) |
| ZA (1) | ZA200800640B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150028858A (ko) * | 2004-11-29 | 2015-03-16 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス， インク． | 酵素阻害のための化合物 |
| WO2007149512A2 (en) | 2006-06-19 | 2007-12-27 | Proteolix, Inc. | Peptide epoxyketones for pr0teas0me inhibition |
| MY173938A (en) | 2007-10-04 | 2020-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| MY159358A (en) * | 2007-10-12 | 2016-12-30 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| EP3545953A1 (en) * | 2008-06-20 | 2019-10-02 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
| AU2009308516B2 (en) | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| KR20110086142A (ko) | 2008-11-11 | 2011-07-27 | 노파르티스 아게 | 핑골리모드의 염 |
| HRP20131106T1 (hr) * | 2008-12-18 | 2013-12-20 | Novartis Ag | Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline |
| AU2009327405A1 (en) | 2008-12-18 | 2011-06-30 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
| CN102256941A (zh) * | 2008-12-18 | 2011-11-23 | 诺瓦提斯公司 | 新的盐 |
| US8673982B2 (en) * | 2009-02-24 | 2014-03-18 | Novartis Ag | Ceramide-analogous metabolites |
| US20100243087A1 (en) * | 2009-03-03 | 2010-09-30 | Millipore Corporation | System and pump apparatus for processing fluid samples |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
| HUE045612T2 (hu) | 2011-01-07 | 2020-01-28 | Novartis Ag | Immunszuppresszáns készítmények |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| RU2496486C1 (ru) | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| CA2920758A1 (en) | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2019064185A1 (en) | 2017-09-27 | 2019-04-04 | Novartis Ag | PARENTERAL FORMULATION COMPRISING SITOMOD |
| CN111132677A (zh) | 2017-09-29 | 2020-05-08 | 诺华股份有限公司 | 西尼莫德的给药方案 |
| RU2020114750A (ru) | 2017-09-29 | 2021-10-29 | Новартис Аг | Схема введения доз сипонимода |
| WO2021214717A1 (en) | 2020-04-23 | 2021-10-28 | Novartis Ag | Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604229A (en) * | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| DE19645549A1 (de) * | 1996-11-05 | 1998-05-07 | Bayer Ag | Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan |
| ES2226110T3 (es) * | 1997-04-04 | 2005-03-16 | Mitsubishi Pharma Corporation | Compuestos de 2-aminopropano-1,3-diol, su uso medico, e intermedios para sintetizarlos. |
| US6727283B2 (en) * | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| US20040235794A1 (en) * | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| MXPA04002679A (es) * | 2001-09-27 | 2004-07-30 | Kyorin Seiyaku Kk | Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos. |
| JP4152884B2 (ja) * | 2001-09-27 | 2008-09-17 | 杏林製薬株式会社 | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 |
| US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| AU2003240655B2 (en) * | 2002-05-16 | 2007-09-06 | Novartis Ag | Use of EDG receptor binding agents in cancer |
| EP1670463A2 (en) * | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
-
2006
- 2006-08-04 GT GT200600350A patent/GT200600350A/es unknown
- 2006-08-07 PE PE2006000957A patent/PE20070337A1/es not_active Application Discontinuation
- 2006-08-07 AR ARP060103432A patent/AR056020A1/es unknown
- 2006-08-07 PE PE2009001335A patent/PE20100149A1/es not_active Application Discontinuation
- 2006-08-08 RU RU2011106364/15A patent/RU2470631C2/ru not_active IP Right Cessation
- 2006-08-08 WO PCT/US2006/030836 patent/WO2007021666A2/en not_active Ceased
- 2006-08-08 TW TW095129275A patent/TWI317289B/zh not_active IP Right Cessation
- 2006-08-08 NZ NZ565696A patent/NZ565696A/en not_active IP Right Cessation
- 2006-08-08 MX MX2008001967A patent/MX2008001967A/es active IP Right Grant
- 2006-08-08 CN CN2006800286163A patent/CN101237852B/zh not_active Expired - Fee Related
- 2006-08-08 EP EP06800936.4A patent/EP1915130B1/en active Active
- 2006-08-08 US US11/997,909 patent/US20080194526A1/en not_active Abandoned
- 2006-08-08 MY MYPI20063826A patent/MY145111A/en unknown
- 2006-08-08 AU AU2006280138A patent/AU2006280138B2/en not_active Ceased
- 2006-08-08 BR BRPI0615009-8A patent/BRPI0615009A2/pt not_active IP Right Cessation
- 2006-08-08 CA CA2618018A patent/CA2618018C/en not_active Expired - Fee Related
- 2006-08-08 JP JP2008526120A patent/JP5068755B2/ja not_active Expired - Fee Related
- 2006-08-08 NZ NZ593121A patent/NZ593121A/xx not_active IP Right Cessation
- 2006-08-08 RU RU2008108887/15A patent/RU2428180C2/ru not_active IP Right Cessation
-
2008
- 2008-01-21 IL IL188915A patent/IL188915A0/en unknown
- 2008-01-22 ZA ZA200800640A patent/ZA200800640B/xx unknown
- 2008-02-05 KR KR1020087003142A patent/KR101473494B1/ko not_active Expired - Fee Related
- 2008-02-08 TN TNP2008000061A patent/TNSN08061A1/en unknown
- 2008-02-08 MA MA30632A patent/MA29736B1/fr unknown
- 2008-02-08 EC EC2008008165A patent/ECSP088165A/es unknown
- 2008-03-07 NO NO20081218A patent/NO20081218L/no not_active Application Discontinuation
-
2012
- 2012-09-07 US US13/606,118 patent/US20120328664A1/en not_active Abandoned
-
2013
- 2013-12-06 US US14/099,072 patent/US20150080347A9/en not_active Abandoned
-
2015
- 2015-10-15 US US14/883,729 patent/US20160030572A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056020A1 (es) | Formulaciones liquidas | |
| MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| EP2983661B1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| JP2013501790A5 (es) | ||
| DK1891038T3 (da) | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer | |
| WO2006099275A2 (en) | Method of treating actinic keratosis | |
| MX2013006187A (es) | Composiciones farmaceuticas. | |
| BR112012021638A2 (pt) | composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MX2019003470A (es) | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. | |
| KR20200052934A (ko) | 경피 제제 | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| BRPI0515344A (pt) | composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |